profit from every $100 of sales.
$0$100
Bausch + Lomb
$21.14-0.84% today
+40.3% in 1 year
1-year low $14.561-year high $21.37
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bausch + Lomb sold, what it kept, and what it did with the cash.
Sales went from $3.77 billion in 2022 to $5.10 billion in 2025, with -$360 million of profit last year.
SalesProfit
Bausch + Lomb vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bausch + Lomb | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.0× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Bausch + Lomb's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 3,412 | 3,765 | 3,768 | 4,146 | 4,791 | 5,101 | |
| – | – | 2,249 | 2,504 | 2,919 | 3,051 | |
| – | – | 220 | 204 | 206 | 188 | |
| 732 | 733 | 598 | 499 | 601 | 525 | |
| -18 | 182 | 6 | -260 | -317 | -360 | |
| -0.05 | 0.52 | 0.02 | -0.74 | -0.90 | -1.02 | |
| – | – | 59.7% | 60.4% | 60.9% | 59.8% | |
| – | – | 5.8% | 4.9% | 4.3% | 3.7% | |
| -0.5% | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | – | 10,823 | 11,144 | 13,442 | 13,469 | 14,022 |
| Cash | 238 | 174 | 354 | 331 | 305 | 383 |
| Total debt | – | – | 2,436 | 4,562 | 4,784 | 5,082 |
| Total liabilities | – | 1,421 | 4,043 | 6,522 | 6,925 | 7,503 |
| – | 9,329 | 7,033 | 6,850 | 6,473 | 6,448 | |
| 350 | 350 | 350 | 351 | 352 | 354 | |
| – | 2.7% | 1.8% | 0.8% | 1.2% | 0.7% | |
| – | 2.0% | 0.1% | -3.8% | -4.9% | -5.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 522 | 873 | 345 | -17 | 232 | 283 | |
| 253 | 193 | 175 | 181 | 291 | 349 | |
| 269 | 680 | 170 | -198 | -59 | -66 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 50 | 62 | 62 | 74 | 92 | 149 |
Valuation
- –
- 26.7×
- –
- 0.9×
- 1.5×
- –
- 23.3×
- -0.9%
- -4.8%
- 0.0%
Profitability
- 59.8%
- 3.7%
- -7.1%
- 13.9%
- 2.6%
- -1.2%
- -3.4%
- -1.6%
- 2.6%
- 7.4%
Growth
- +8.4%
- –
- −11.9%
- –
- +0.3%
Financial health
- 9.0×
- 0.01
- 0.3%
- 0.7×
- 1.53
- 0.99
- 0.38
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 41%of 952
Bottom 35%of 883
Bottom 40%of 870
Bottom 34%of 985
What analysts expect
- Average price target
- $19.00
- Range
- $16.00 – $21.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 0.08 | 0.06 | +33.3% |
| Feb 18, 2026 | 0.32 | 0.35 | −8.6% |
| Oct 29, 2025 | 0.18 | 0.16 | +12.5% |
| Jul 30, 2025 | 0.07 | 0.06 | +16.7% |
| Apr 30, 2025 | -0.07 | 0.03 | −333.3% |
| Feb 19, 2025 | 0.25 | 0.24 | +4.2% |
| Oct 30, 2024 | 0.17 | 0.16 | +6.3% |
| Jul 31, 2024 | 0.13 | 0.13 | +0.0% |
News
Bausch + Lomb Corporation Q3 2026 Earnings Call SummaryYahoo Finance · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
56No pass
Philip Fisher
32No pass
Peter Lynch
43No pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
19No pass
Questions about Bausch + Lomb
Is Bausch + Lomb a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bausch + Lomb AI analysis
What does Bausch + Lomb do?
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. It is in Medical - Instruments & Supplies, based in Vaughan, ON, Canada, with 13,000 employees.
Does Bausch + Lomb pay a dividend?
No. Bausch + Lomb does not pay a dividend at the moment.
Is Bausch + Lomb stock halal?
No. Bausch + Lomb does not pass our halal screen: its debt is 67% of its market value, at or above the 33% limit. How we check
How has Bausch + Lomb stock done over the past year?
Up 40.3% over the past twelve months, to $21.14. It traded between $14.56 and $21.37, close to its high.
Who are Bausch + Lomb's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Bausch + Lomb's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.